Who Paid My Doc
Mark Falimirski
Surgical Critical Care Indianapolis, IN Medical Doctor
NPI 1528026176 CMS profile 69018
1001 W 10Th St, Indianapolis, IN 46202
General payments
$184
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Mark Falimirski of Indianapolis, IN is reported in the CMS Open Payments database as having received $184 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 20th percentile of Surgical Critical Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $100 | 1 | |
| 2022 | General | $84 | 2 |
Beside peers
- Mark Falimirski
- Surgical Critical Care median
- Middle half of Surgical Critical Care
- National median
In program year 2025, general payments to Mark Falimirski were reported at $100. Among 1,068 Surgical Critical Care profiles paid that year, the median was $231 and the middle half received between $82 and $1,489.
Show as a table
| Year | Mark Falimirski | Surgical Critical Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $161 | $57–$631 | $163 |
| 2020 | $0 | $116 | $33–$383 | $114 |
| 2021 | $0 | $121 | $37–$475 | $132 |
| 2022 | $84 | $163 | $53–$789 | $149 |
| 2023 | $0 | $188 | $67–$1,031 | $160 |
| 2024 | $0 | $216 | $80–$1,133 | $164 |
| 2025 | $100 | $231 | $82–$1,489 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 34 billing codesPaid by Medicare
$47,745
Medicare patients
156
Services billed
417
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 52% | |
| Arthritis | 51% | |
| Ischemic heart disease | 47% | |
| Depression | 47% | |
| Chronic kidney disease | 40% | |
| Heart failure | 39% | |
| Atrial fibrillation | 37% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Surgical Critical Care in Indiana
Lawrence Lottenberg
Surgical Critical Care · Fort Wayne, IN
Timothy Pohlman
Surgical Critical Care · Fort Wayne, IN
Roland Thomas
Surgical Critical Care · Valparaiso, IN
Rachael Springer
Surgical Critical Care · Indianapolis, IN
Samantha Tarras
Surgical Critical Care · Indianapolis, IN
William Peery
Surgical Critical Care · Fort Wayne, IN
Related records
Surgical Critical Care in Indiana
Practitioners in the same specialty and state, ranked by reported value.
All Surgical Critical Care
Everyone recorded under this specialty, nationwide.
Doctors in Indiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.